MedTrace Logo

Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)

NCT00313781 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 204

Last updated 2013-04-11

Study results available
· View outcomes & findings →

Summary

To test the efficacy of CP-751,871 combined with docetaxel and prednisone in the treatment of prostate cancer that is refractory to hormone therapy

Conditions

  • Prostatic Neoplasms

Interventions

DRUG

CP-751,871

CP-750,871 is administered intravenously at a dose of 20 mg/kg on day 1 of each 21-day cycle (for patient convenience and logistical management, the dose of CP-751,871 may be deferred up to 7 days).

DRUG

docetaxel

Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.

DRUG

prednisone

Prednisone is administered at a dose of 5 mg twice daily.

DRUG

docetaxel

Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.

DRUG

prednisone

Prednisone is administered at a dose of 5 mg twice daily.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2011-04-30
Completion
2011-12-31

Countries

  • United States
  • Canada
  • Germany
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00313781 on ClinicalTrials.gov